BRTX Archives - BioTuesdays

Developments

BioRestorative Therapies preliminary BRTX-100 Phase 2 data for cLDD bolsters confidence in trial hitting primary and secondary endpoints

BioRestorative Therapies (NASDAQ:BRTX) announced new preliminary 26–52 week blinded data from the first 10 patients with chronic lumbar disc disease (cLDD) enrolled in the ongoing Phase 2 clinical trial of BRTX-100...

November 13, 2024

Developments

BioRestorative expands IP protecting ThermoStem cell-based metabolic disease therapy program

BioRestorative Therapies (NASDAQ:BRTX) has announced that the Israel Patent Office has issued a Notice of Allowance for a new patent application, covering several fundamental elements of its allogeneic, off-the-shelf...

October 31, 2024

Markets

Rodman & Renshaw starts BioRestorative Therapies at buy; PT $15

Rodman & Renshaw launched coverage of BioRestorative Therapies (NASDAQ:BRTX) with a “buy” rating and $15 target price. The stock closed at $2.02 on June 26. BioRestorative develops therapeutic products using cell...

June 27, 2024

Developments

BioRestorative Therapies gains media attention for key regenerative medicine programs

Benzinga editor, Tony Noto, interviewed Lance Alstodt, BioRestorative’s (NASDAQ:BRTX) Chief Executive Officer, about the company’s two core clinical development programs (BRTX-100 targeting disc/spine disease and...

June 20, 2024

Developments

BioRestorative in substantive discussions with prospective licensing partner for ThermoStem metabolic disease program

BioRestorative Therapies (NASDAQ:BRTX) reports that it is engaged in substantive discussions with an undisclosed commercial stage regenerative medicine company concerning the licensing of its proprietary off-the-shelf...

June 13, 2024

Developments

BioRestorative Therapies and Cartessa Aesthetics collaborate to build a vertically integrated, best-in-class biocosmeceutical platform

BioRestorative Therapies (NASDAQ:BRTX) announced that it has entered into a five-year exclusive supply agreement with Cartessa Aesthetics. The goal of this transformative agreement is to combine BioRestorative’s deep...

April 30, 2024

Feature

BioRestorative Therapies propelling cell-based therapies for lower back pain, Obesity, Type 2 diabetes and more

BioRestorative Therapies (NASDAQ:BRTX) is a fully integrated regenerative medicine company with preclinical and Phase 2 clinical programs focused on conditioning the bodies’ regenerative potential to treat major...

March 5, 2024

Developments

BioRestorative Therapies posts positive preliminary Phase 2 data for cLDD

BioRestorative Therapies (NASDAQ:BRTX) announced the public availability of a poster, presented yesterday at the Orthopaedic Research Society’s 2024 Annual Meeting, which describes preliminary 26 and 52 week blinded...

February 5, 2024

Markets

Maxim starts BioRestorative Therapies at buy; PT $6

Maxim Group initiated coverage of BioRestorative Therapies (NASDAQ:BRTX) with a “buy” rating and $6 price target. The stock closed at $2.46 on Sept. 27. BioRestorative is a cell therapy company developing BRTX-100 for...

September 28, 2022

Tag - BRTX

BioRestorative Therapies preliminary BRTX-100 Phase 2 data for cLDD bolsters confidence in trial hitting primary and secondary endpoints

BioRestorative expands IP protecting ThermoStem cell-based metabolic disease therapy program

Rodman & Renshaw starts BioRestorative Therapies at buy; PT $15

BioRestorative Therapies gains media attention for key regenerative medicine programs

BioRestorative in substantive discussions with prospective licensing partner for ThermoStem metabolic disease program

BioRestorative Therapies and Cartessa Aesthetics collaborate to build a vertically integrated, best-in-class biocosmeceutical platform

BioRestorative Therapies propelling cell-based therapies for lower back pain, Obesity, Type 2 diabetes and more

BioRestorative Therapies posts positive preliminary Phase 2 data for cLDD

Maxim starts BioRestorative Therapies at buy; PT $6

General

More